For a subgroup of patients with ECOG 0–1, rwToT was 9.4 (95% CI: 5.0–20.8), 7.1 (95% CI: 5.0–10.1), and 2.9 (95% CI: 2.2–4.1) months for patients who received PD-1/PD-L1 inhibitor monotherapy, PD-1/PD-L1 inhibitor combination, and PBC combination, respectively. The gene discussed is CD274; the disease is primary biliary cholangitis.